最新ニュース 2seventy bio (NASDAQ:TSVT) 株価情報

2seventy bio

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

2seventy bio Inc

Trading Ideas

HCAI

Huachen AI Parking Management Technology Holding Co. Shares Halted On Circuit Breaker To The Upside, Stock Now Up 33%

As China's tech sector stages a strong comeback, investors are increasingly looking at <a href="https://www.benzinga.com/etfs">ETFs as a way to gain exposure</a> to this space. 
Whether it's internet giants, broad technology firms, or a mix of leading Chinese companies, ETFs offer a diversified way to take a bite of surrounding China's innovation boom.
Here are three ETFs that provide investors with access to China's rebounding tech sector.
Also Read: <a href="https://www.benzinga.com/news/global/25/01/43315374/ai-etfs-in-focus-as-alibaba-challenges-deepseek-with-new-model">AI ETFs In Focus As Alibaba Challenges DeepSeek With New Model</a>
<ul>
<li>Invesco China Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQQQ#NYSE">CQQQ</a>): This ETF provides concentrated exposure to China's tech giants. It also mirrors the FTSE China Incl A 25% Technology Capped Index, which includes major players like Tencent (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>), PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), and Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), companies at the forefront of AI, e-commerce, and cloud computing. Recently, Baidu Cloud and Tencent Cloud integrated DeepSeek&#8217;s AI model into their platforms. With DeepSeek's upward rise, both companies witnessed a surge, and pulled CQQQ up along with it. The ETF has rallied 13.5% year-to-date and 45% in the past year.</li>
</ul>
<ul>
<li>KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>): This ETF provides exposure to China's big internet names, mirroring the CSI Overseas China Internet Index. The fund&#8217;s holdings include major players like Alibaba (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Tencent, and Baidu. Alibaba's latest AI model has <a href="https://www.benzinga.com/25/01/43311376/alibaba-unveils-qwen25-max-claims-it-beats-deepseek-and-openai-in-ai-performance-race">reportedly outperformed</a> Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Llama and DeepSeek's V3 in various tests. This led the company's stock to surge, lifting KWEB along with it. As Wall Street brokers turn more optimistic on China's valuation discount disappearing, KWEB stands to benefit from increased foreign inflows. The ETF has grown 12.6% year-to-date and 32.5% in the past year.</li>
</ul>
<ul>
<li>iShares MSCI China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>): This ETF provides a broader exposure while maintaining access to substantial allocation to technology stocks. China's largest and most liquid companies, including Tencent, Alibaba, Meituan and Xiaomi are among MCHI&#8217;s holdings. HSBC recently noted that the valuation gap between China and emerging markets may narrow as global funds flow into Chinese stocks. Deutsche Bank echoed the sentiment.</li>
</ul>
<h3 class="wp-block-heading">Market Overview</h3>
The Hang Seng Tech Index is currently trading at 17 times forward earnings estimates, significantly cheaper than the Nasdaq 100's 27 times valuation, according data compiled by Bloomberg. This suggests ample room for price appreciation, making MCHI an appealing option. The ETF has climbed 8.32% this year thus far, and 31.25% in the past 12 months.
After years of regulatory headwinds and economic uncertainty, China's tech sector is making a roaring comeback. A surge in AI innovation and favorable valuations have propelled the Hang Seng Tech Index into a bull market, with Wall Street analysts increasingly bullish on the space, said Bloomberg in a report. Heavyweights like Xiaomi and Alibaba are among the companies leading the rally.
Meanwhile, Bloomberg reported that analysts at Deutsche Bank argue that China's innovation-driven resurgence will force global investors to turn sharply toward the nation's stocks, despite geopolitical risks.
Favorable valuations have helped reinforce the upbeat sentiment. As Deutsche Bank's Peter Milliken put it in a research note: "We think 2025 is the year the investing world realizes China is outcompeting the rest of the world." 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43565442/exclusive-defiance-ceo-talks-about-the-new-orcx-etf-launch-and-all-things-ai">EXCLUSIVE: Defiance CEO Talks About The New ORCX ETF Launch And All Things AI</a></li>
</ul>
Photo: Shutterstock

Asia

BABA

BIDU

CHIK

CQQQ

KWEB

MCHI

TCEHY

China Tech ETFs Surge As DeepSeek-Led AI Boom Fuels Bull Market

WIIM

CNDT

Conduent shares are trading higher following a Reuters report suggesting the company is exploring a sale.

Conduent Shares Halted On Circuit Breaker To The Upside, Stock Now Up 10.2%

News

Asset Sales

Conduent Exploring A Sale After Receiving Takeover Interest, Sources Say

In the current market session, Coupang Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) stock price is at $23.73, after a 0.57% drop. However, over the past month, the company's stock spiked by 11.18%, and in the past year, by 58.17%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1738961112_0.png" alt="Past Year Chart" />

<h3>How Does Coupang P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 24.18 in the Broadline Retail industry, Coupang Inc. has a higher P/E ratio of 41.94. Shareholders might be inclined to think that Coupang Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1738961112_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

CPNG

Price Over Earnings Overview: Coupang

Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) has outperformed the market over the past 5 years by 4.86% on an annualized basis producing an average annual return of 17.23%. Currently, Liberty Energy has a market capitalization of $2.83 billion. 
Buying $1000 In LBRT: If an investor had bought $1000 of LBRT stock 5 years ago, it would be worth $2,191.27 today based on a price of $17.31 for LBRT at the time of writing.
<h3>Liberty Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738961108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LBRT

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Editor&#8217;s note: This story has been updated to correct a paragraph written about the Coca-Cola Co, not Coca-Cola Consolidated Inc. 
The U.S. Department of Agriculture said Wednesday that six dairy herds in Nevada have tested positive for a strain of bird flu associated with a <a href="https://www.benzinga.com/general/restaurants/25/02/43511263/high-egg-prices-drive-waffle-house-to-add-50-cent-surcharge">man's death in January.</a>
The Details: The infected Nevada cows mark the first time the D1.1 variant of the H5N1 bird flu has been detected in cattle, which means the cows contracted the virus from birds and not another herd of cattle. 
This is the second time a type of bird flu has been introduced into cattle herds by wild birds, according to a CNN <a href="https://www.cnn.com/2025/02/05/health/bird-flu-cattle-nevada/index.html">report</a>. If wild birds are spreading the disease to cattle, it could become endemic, or continuously circulating.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a>
"In my opinion, it is now endemic, and it should be classified as an endemic virus," Dr. Louise Moncla, a pathobiologist at the University of Pennsylvania, told CNN.&nbsp;
The D1.1 variant is the strain associated with a Louisiana man's death in January and a severe case contracted by a teenager in British Columbia who was hospitalized in critical condition last fall.&nbsp;
Michael Worobey, an evolutionary biologist at the University of Arizona who has studied the H5N1 virus in cattle, <a href="https://fortune.com/well/2025/02/06/new-bird-flu-spread-cows-nebraska-expert-warns-could-worse-covid/">told</a> Fortune that the virus has the potential to "make COVID seem like a walk in the park" and federal officials should quickly share information in order to stop the spread.&nbsp;
That may be hard to do, considering the Trump administration in late January <a href="https://www.benzinga.com/general/health-care/25/01/43194764/trump-administration-halts-all-communications-from-the-centers-for-disease-control-as-bird-flu-spreads">ordered all</a> communications from the Centers for Disease Control and Prevention to stop. The pause in communications includes the CDC&#8217;s Morbidity and Mortality Weekly Report, a scientific publication on health information and recommendations.
Stocks To Watch: According <a href="https://www.aphis.usda.gov/livestock-poultry-disease/avian/avian-influenza/hpai-detections/hpai-confirmed-cases-livestock">to the USDA</a>, H5N1 avian influenza has been detected in 957 herds in 16 states. Companies exposed to the dairy industry are on watch due to the uncertainty surrounding bird flu in cattle herds. 
Coca-Cola Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) has over 80 dairy products under 15 brands including Fairlife milk and Core Power protein shakes and would likely be sensitive to dairy price increases or shortages. 
Chocolate makers like Hershey Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) and Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) are also heavily exposed to the dairy industry as milk is one of their top ingredients.&nbsp;
General Mills Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>), maker of Häagen-Dazs ice cream, Yoplait and Oui French-style yogurt, should also be monitored as the bird flu situation develops.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details">Ford Shares Skid After Q4 Report: Details</a></li>
</ul>
Photo: Labellepatine via Shutterstock

Government

Large Cap

Health Care

General

COKE

MDLZ

Deadly Bird Flu Strain Hits Dairy Cows: 'Could Make COVID Seem Like A Walk In The Park,' Expert Says (CORRECTED)

Needham analyst Charles Shi reiterates Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Buy and maintains $120 price target.

Price Target

Reiteration

Analyst Ratings

ENTG

Needham Reiterates Buy on Entegris, Maintains $120 Price Target

When most people hear Hasbro Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) they think of the company's toys and games like Transformers, G.I. Joe, Monopoly, Nerf and Play-Doh. Thanks to a new entertainment announcement, investors could soon focus more on the company's <a href="https://www.benzinga.com/news/22/02/25725395/100-upside-what-a-wizards-of-the-coast-spinoff-could-mean-for-hasbro">Wizards of the Coast division.</a>
What Happened: Hasbro Entertainment is launching a film and television universe based on the Magic: The Gathering game, which comes as the brand saw strong growth in<a href="https://www.benzinga.com/news/earnings/24/10/41515616/monopoly-maker-hasbro-inventory-falls-39-in-q3-cfo-vows-to-finish-2024-with-improved-profitability"> the third quarter</a>.
Magic: The Gathering, launched in 1993 by Wizards of the Coast, was the world's first trading card game and became a staple in the sector over the years. Hasbro acquired Wizards of the Coast in 1999 and in recent years has seen increased growth from the sector thanks to digital gaming.
Hasbro is teaming up with Legendary Entertainment, a leading entertainment company that counts Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) as its co-owner with Legendary.
Legendary Entertainment and Hasbro plan to launch a movie first and then expand into television, following a similar path of the "Dune" franchise, which Legendary Entertainment also worked on, as <a href="https://www.hollywoodreporter.com/movies/movie-news/magic-the-gathering-film-tv-universe-1236129132/">reported </a>by The Hollywood Reporter. 
"We pride ourselves on being thoughtful caretakers of singular, beloved IP, and no property better fits that description than Magic: The Gathering," Legendary's Chairwoman of worldwide production Mary Parent said.
Legendary has worked on turning brands into franchises before with Dune, Godzilla Vs. Kong and the upcoming "Minecraft" movie.
Hasbro has a Magic: The Gathering TV show in the works for Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>). A planned movie was in the works for years but never was created.
"This is an exciting and complementary partnership, uniting one of the world' most iconic brands with a powerful and proven steward," Hasbro Entertainment head of film Zev Foreman said.
Read Also: <a href="https://www.benzinga.com/general/entertainment/23/08/33526418/post-malone-buys-rarest-magic-the-gathering-lord-of-the-rings-card-heres-how-much-he-report">Post Malone Snags Magic: The Gathering&#8217;s Rarest Lord Of The Rings Card: Here&#8217;s How Much He Reportedly Spent</a>
Why It's Important: Magic: The Gathering has been played by 50 million people around the world and has a strong built-in fan base that could translate to a strong reception for the movies and TV shows.
Not all game adaptations work out successfully as several Dungeons &amp; Dragons movies did not perform strongly at the box office. Wizards of the Coast also owns Dungeons &amp; Dragons.
Hasbro has played a key role in adapting its brands into movies and TV shows, including the popular Transformers franchise.
The partnership with Legendary could be the key here as the company has successfully turned Dune into a strong movie and TV franchise.
Hasbro's Wizards of the Coast and Digital Gaming segment continues to be a strong performer for the company and with the latest entertainment news could provide more upside for shareholders.
In 2022, an activist shareholder pushed for Hasbro to spinoff Wizards of the Coast, suggesting there could be significant upside for Hasbro's share price by unlocking the key growth segment.
HAS Price Action: Hasbro stock trades at $58.92 versus a 52-week trading range of $46.10 to $73.46.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/02/43442219/why-beer-tequila-avocados-cars-iphone-prices-could-rise-trumps-tariffs-on-canada-mexico-china-to-hurt-several-sectors">Why Beer, Tequila, Avocados, Cars, iPhone Prices Could Rise: Trump&#8217;s Tariffs On Canada, Mexico, China To Hurt Several Sectors</a></li>
</ul>
Photo: charnsitr/Shuttersock.com

Entertainment

Gaming

NFLX

Hasbro Moves To Expand Magic: The Gathering Into Film & TV — Why Legendary Matters

Needham analyst James Ricchiuti reiterates Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) from Hold to Hold.

PRLB

Needham Reiterates Hold on Proto Labsto Hold

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) with a Buy and maintains $51 price target.

IMVT

HC Wainwright & Co. Reiterates Buy on Immunovant, Maintains $51 Price Target

Legal

Delaware Judge Dismisses Lawsuit Against Hertz Related To Redemption Of Warrants, Recent Financing Transactions

<a href="https://www.cnbc.com/2025/02/07/hims-hers-faces-lawmaker-scrutiny-over-misleading-super-bowl-ad-.html">https://www.cnbc.com/2025/02/07/hims-hers-faces-lawmaker-scrutiny-over-misleading-super-bowl-ad-.html</a>
<ul>
<li>Hims &amp; Hers is under fire over an ad for its weight loss offerings that's slated to run during the Super Bowl on Sunday.</li>
<li>Two U.S. senators expressed concern over an "upcoming advertisement" that "risks misleading patients by omitting any safety or side effect information."</li>
<li>Hims &amp; Hers' ad is called "Sick of the System" and sharply criticizes the $160 billion dollar weight loss industry.</li>
</ul>
<a href="https://www.cnbc.com/quotes/HIMS/">Hims &amp; Hers</a> is facing <a href="https://www.durbin.senate.gov/newsroom/press-releases/durbin-marshall-draw-fda-attention-to-misleading-drug-commercial-set-to-run-during-super-bowl">scrutiny from lawmakers</a> over what they claim is a "misleading" advertisement for its weight loss offerings that's slated to run during the Super Bowl on Sunday.
Sens. Dick Durbin (D-Ill.) and Roger Marshall (R-Kan.) wrote a letter to the U.S. Food and Drug Administration on Friday expressing concerns over an "upcoming advertisement" that "risks misleading patients by omitting any safety or side effect information when promoting a specific type of weight loss medication."
&nbsp;
The Hims &amp; Hers ad, which the company <a href="https://www.youtube.com/watch?v=l5l6QMNnqoc">released online</a> in late January, is called "Sick of the System" and sharply criticizes the $160 billion dollar weight loss industry. It shows visuals of existing weight loss medications known as GLP-1s, including injection pens that look like <a href="https://www.cnbc.com/quotes/NVO/">Novo Nordisk's</a> blockbuster diabetes drug Ozempic.
The ad claims those drugs are "priced for profits, not patients," and points to Hims &amp; Hers' weight loss medications as "affordable" and "doctor-trusted" alternatives.
"We are complying with existing law and are happy to continue working with Congress and the new Administration to fix the broken health system and ensure that patients have choices for quality, safe, and affordable healthcare," a Hims &amp; Hers spokesperson told CNBC in a statement.
The senators do not mention Hims &amp; Hers by name in their letter, but they do reference some of the visuals in the ad, including "imagery of an injection pen with distinctive characteristics reflective of an existing brand-name medication."
"Nowhere in this promotion is there any side effect disclosure, risk, or safety information as would be typically required in a pharmaceutical advertisement," the senators wrote. "Further, for only three seconds during the minute-long commercial does the screen flash in small, barely legible font, that these products are not FDA-approved."
&nbsp;
Hims &amp; Hers began offering&nbsp;<a href="https://www.cnbc.com/2024/05/20/hims-hers-compounded-glp-1-injections.html">compounded semaglutide</a>&nbsp;through its platform in May after launching a new weight loss program in late 2023. Semaglutide is the active ingredient in Ozempic and Wegovy, which can each cost around $1,000 a month without insurance.
Shares of Hims &amp; Hers <a href="https://www.cnbc.com/2024/12/24/digital-health-stocks-pummeled-by-wall-street-in-2024-but-hims-surges.html">jumped</a> over 170% last year, thanks to soaring demand for GLP-1s.&nbsp;They rose another 8% on Friday, lifting the company's market cap to about $9.5 billion.
Compounded GLP-1s are typically much cheaper and can serve as an alternative for patients that are navigating complex supply hurdles and spotty insurance coverage. Hims &amp; Hers sells compounded semaglutide for under $200 a month.
The FDA doesn't review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient's needs. Compounded products can also be produced when brand-name treatments are in&nbsp;<a href="https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers">shortage</a>.
Semaglutide is currently in shortage, according to the <a href="https://dps.fda.gov/drugshortages/searchresult?type=semaglutide">FDA</a>.
Sens. Durbin and Marshall said that advertisements for brand-name GLP-1 medications include "significant risk disclosures to patients about side effects and contraindications, including warnings about potential gallbladder, pancreas, vomiting, diarrhea, and other implications."
A release on Durbin's website says that the ad in question appears to exploit a loophole "regarding promotions of compounded drugs by telehealth companies."
The senators said they believe the FDA may have the authority to take enforcement actions against marketing that could mislead patients, and they plan to introduce new legislation to address regulatory loopholes.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

"Hims & Hers Faces Scrutiny From Lawmakers Over 'Misleading' Super Bowl Ad" - CNBC

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Solitario Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XPL#AMEX">XPL</a>) with a Buy and maintains $1.2 price target.

HC Wainwright & Co. Reiterates Buy on Solitario Resources, Maintains $1.2 Price Target

TDOC

Teladoc shares are trading higher on continued strength amid bullish comments Citron Research.

<a href="https://www.dsca.mil/press-media/major-arms-sales/israel-munitions-guidance-kits-fuzes-and-munitions-support">https://www.dsca.mil/press-media/major-arms-sales/israel-munitions-guidance-kits-fuzes-and-munitions-support</a>
&nbsp;
<a href="https://www.dsca.mil/press-media/major-arms-sales/israel-agm-114-hellfire-missiles">https://www.dsca.mil/press-media/major-arms-sales/israel-agm-114-hellfire-missiles</a>
&nbsp;
&nbsp;

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

U.S. State Dept Approves Potential Sale Of Munitions, Guidance Kits, Fuses, And Munitions Support To Israel For An Estimated $6.75B; Approves Potential Sale Of Hellfire Missiles To Israel For An Estimated $660M

RBC Capital analyst Deane Dray maintains nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) with a Outperform and raises the price target from $85 to $86.

RBC Capital Maintains Outperform on nVent Electric, Raises Price Target to $86

Financial giants have made a conspicuous bearish move on Tempus AI. Our analysis of options history for Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) revealed 49 unusual trades.
Delving into the details, we found 36% of traders were bullish, while 42% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $52,770, and 47 were calls, valued at $3,193,431.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $100.0 for Tempus AI, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Tempus AI's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Tempus AI's significant trades, within a strike price range of $20.0 to $100.0, over the past month.
<h3>Tempus AI Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738960236_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$5.7</td>
<td>$5.1</td>
<td>$5.1</td>
<td>$80.00</td>
<td>$472.0K</td>
<td>6.9K</td>
<td>0</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$3.5</td>
<td>$3.3</td>
<td>$3.5</td>
<td>$90.00</td>
<td>$203.4K</td>
<td>11.0K</td>
<td>1.3K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.0</td>
<td>$25.9</td>
<td>$26.78</td>
<td>$50.00</td>
<td>$133.6K</td>
<td>2.8K</td>
<td>211</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$27.0</td>
<td>$26.3</td>
<td>$26.5</td>
<td>$50.00</td>
<td>$132.5K</td>
<td>2.8K</td>
<td>314</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$26.9</td>
<td>$26.1</td>
<td>$26.43</td>
<td>$50.00</td>
<td>$132.1K</td>
<td>2.8K</td>
<td>96</td>
</tr>
</tbody>
</table>

<h3>About Tempus AI</h3>
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
After a thorough review of the options trading surrounding Tempus AI, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Tempus AI's Current Market Status</h3>
<ul>
<li>With a volume of 14,494,605, the price of TEM is up 2.62% at $66.69. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Tempus AI</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $60.666666666666664.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $56. 
&#x2A; An analyst from Loop Capital persists with their Buy rating on Tempus AI, maintaining a target price of $52. 
&#x2A; An analyst from TD Cowen downgraded its action to Buy with a price target of $74. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Tempus AI, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Market Whales and Their Recent Bets on TEM Options

Financial giants have made a conspicuous bearish move on Newmont. Our analysis of options history for Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) revealed 23 unusual trades.
Delving into the details, we found 39% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $570,360, and 20 were calls, valued at $858,091.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $70.0 for Newmont during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Newmont's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Newmont's whale activity within a strike price range from $30.0 to $70.0 in the last 30 days. 
<h3>Newmont Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738960231_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$2.31</td>
<td>$2.21</td>
<td>$2.22</td>
<td>$40.00</td>
<td>$266.4K</td>
<td>3.9K</td>
<td align="right">0</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$3.05</td>
<td>$2.98</td>
<td>$3.05</td>
<td>$42.50</td>
<td>$152.4K</td>
<td>1.8K</td>
<td align="right">50</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.65</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$45.00</td>
<td>$151.5K</td>
<td>3.7K</td>
<td align="right">425</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$7.1</td>
<td>$7.05</td>
<td>$7.05</td>
<td>$40.00</td>
<td>$70.5K</td>
<td>2.8K</td>
<td align="right">189</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$7.05</td>
<td>$6.95</td>
<td>$7.0</td>
<td>$40.00</td>
<td>$70.0K</td>
<td>2.8K</td>
<td align="right">289</td>
</tr>
</tbody>
</table>

<h3>About Newmont</h3>
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.
After a thorough review of the options trading surrounding Newmont, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Newmont's Current Market Status</h3>
<ul>
<li>With a volume of 5,326,332, the price of NEM is up 0.3% at $45.01. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 13 days.</li>
</ul>
<h3>Expert Opinions on Newmont</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $50.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Scotiabank keeps a Sector Perform rating on Newmont with a target price of $50. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Newmont with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Newmont Unusual Options Activity

2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call Transcript

2Seventy Bio, Inc. ( ($TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its investors. ...

2seventy bio Reports Strong Growth in Abecma Sales

TD Cowen analyst Yaron Werber maintained a Hold rating on 2seventy bio (TSVT – Research Report) today. The company's shares closed yesterday at $4....

TD Cowen Reaffirms Their Hold Rating on 2seventy bio (TSVT)

Medigene announced a $1M milestone payment from Regeneron (REGN) was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisit...

Regeneron pays $1M milestone payment to Medigene

Leerink Partners analyst Daina Graybosch reiterated a Buy rating on 2seventy bio (TSVT – Research Report) on December 4 and set a price target of $...

2seventy bio: Buy Rating Amidst Challenges and Growth Potential in BCMA CAR-T Therapy

Tracking Baker Brothers Portfolio - Q3 2024 Update

2seventy bio: All In On Abecma Multiple Myeloma Treatment

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)

Bristol-Myers Squibb slips as 2025 outlook disappoints

ABBV

ABCL

ACAD

ALGS

ALKS

AMGN

ARGNF

ARGX

AVTE

AZNCF

BCLYF

BCYC

BEIGF

BGNE

BMEA

BMYMP

BNTX

CERS

DNLI

EWTX

FBCG

GILD

GLAXF

GLUE

GMAB

GNMSF

HOOK

IGMS

IMCR

IMTX

INCY

INSM

IOVA

ITCI

KALA

KNSA

KYMR

LEGN

LGND

MDGL

MRNA

NRIX

NVSEF

RARE

REGN

REPL

RVMD

RYTM

SGMT

SMMT

SNYNF

STOK

SUPN

TCRX

TEVA

TEVJF

TKPHF

TRDA

TSVT

VTRS

VTVT

Press Releases

TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results

Comments

2seventy bio

ニュース

最新ニュース 2seventy bio (NASDAQ:TSVT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル